In fact, high protein levels of SYF2 were associated with bad prognosis in breast cancer (53), and we found that ZRANB2 mRNA levels were up-regulated 5.4 fold (P < 0.002) in a published dataset of non-responding versus responding breast tumors analyzed before chemotherapy using eprirubicin (54). Here, ZRANB2 is linked to breast carcinoma.